Krex Pharmaceuticals Inc San Diego, CA - 92121

Krex Pharmaceuticals Inc is categorized under Commercial Medical Research in San Diego, CA and active since 2005.

Krex Pharmaceuticals Inc was established in 2005, and today employs 1 to 4, earning $100.000 to $499.999 per year. This is a Commercial Medical Research business, which does work in the B2B market, and is classified as a Commercial Medical Research, under code number 541712 by the NAICS.

If you are seeking more information, feel free to contact Ying Su at the company’s single location by writing to 9823 Pcf Heights Boulevard # F, San Diego, California CA 92121 or by phoning (858) 205-3668. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Krex Pharmaceuticals Inc
Contact Person: Ying Su
Address: 9823 Pcf Heights Boulevard # F, San Diego, California 92121
Phone Number: (858) 205-3668
Annual Revenue (USD): $100.000 to $499.999
Founded: 2005
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Medical Research
SIC Code: 8731
NAICS Code: 541712
Share This Business:

Krex Pharmaceuticals Inc was started in 2005 to provide professional Commercial Medical Research under the SIC code 8731 and NAICS code 541712. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $100.000 to $499.999 per annum.

Feel free to contact Ying Su for inquiries that concern Krex Pharmaceuticals Inc by calling the company number (858) 205-3668, as your correspondence is most welcome. Additionally, the physical location of the single location of Krex Pharmaceuticals Inc can be found at the coordinates 32.899969,-117.189034 as well as the street address 9823 Pcf Heights Boulevard # F in San Diego, California 92121.

For its online presence, you may visit Krex Pharmaceuticals Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.